Request a FREE Sample of our FcRn Binding Kit!Request a FREE Sample of our Fc gamma RI / CD64 Binding Kit !
Happy Holiday! Limited Keychain here with your next orderHappy Holiday! Limited Keychain here with your next order
Request a FREE sample of our GMP products! Request a FREE sample of our GMP products!
Project Name | Project Stage | Molecule Type | Host Species | Therapeutic Area | Indications |
CD16a VHH - 01 | PCC | Solid Tumor | Solid tumor,Hematoma |
Expression analysis of human CD16a on CHO/Human CD16a (158V) Stable Cell Line by FACS.
Cell surface staining using PE-labeled anti-human CD16a antibody was performed on CHO/Human CD16a (158V) Stable Cell Line with different expression levels: CHO/Human CD16a (158V) Stable Cell Line (Low Expression); CHO/Human CD16a (158V) Stable Cell Line (Medium Expression); CHO/Human CD16a (158V) Stable Cell Line (High Expression).
Expression analysis of human CD16a on CHO/Human CD16a (158V) Stable Cell Line by FACS.
Cell surface staining using PE-labeled anti-human CD16a antibody was performed on CHO/Human CD16a (158V) Stable Cell Line with different expression levels: CHO/Human CD16a (158V) Stable Cell Line (Low Expression); CHO/Human CD16a (158V) Stable Cell Line (Medium Expression); CHO/Human CD16a (158V) Stable Cell Line (High Expression).
Human CD16a (F176, S197P) Protein, His Tag (Cat. No. CDA-H52H6) captured on CM5 chip via anti-His antibody can bind Rituximab with an affinity constant of 0.414 μM as determined in a SPR assay (Biacore 8K) (QC tested).
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Acimtamig | AFM-13 | Phase 2 Clinical | The University Of Texas MD Anderson Cancer Center | Lymphoma, T-Cell, Peripheral; Hodgkin Disease; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Mycosis Fungoides | Details |
AFM-24 | AFM-24 | Phase 2 Clinical | Affimed | Solid tumours | Details |
IPH-6501 | IPH-6501; IPH-65 | Phase 2 Clinical | Innate Pharma SA | Neoplasms; Lymphoma, Non-Hodgkin | Details |
SAR445514 | SAR445514; SAR-445514; IPH6401/SAR514 | Phase 2 Clinical | Sanofi | Immunoglobulin Light-chain Amyloidosis; Multiple Myeloma | Details |
SAR-443579 | SAR-443579; SAR443579; SAR579; IPH6101; IPH-6101 | Phase 2 Clinical | Sanofi | Hematologic Diseases; Myelodysplastic Syndromes; Blastic Plasmacytoid Dendritic Cell Neoplasm; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell; Leukemia, Myeloid, Acute | Details |
FT-538 | FT-538 | Phase 2 Clinical | Fate Therapeutics Inc | Leukemia, Myeloid; Ovarian Neoplasms; Solid tumours; HIV Infections; Coronavirus Disease 2019 (COVID-19); Neoplasms; Respiratory Distress Syndrome, Adult; Peritoneal Neoplasms; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Fallopian Tube Neoplasms | Details |
GMA-161 | GMA-161 | Phase 1 Clinical | Sanofi, Macrogenics Inc | Purpura, Thrombocytopenic, Idiopathic | Details |
FT-576 | FT-576 | Phase 1 Clinical | University Of Minnesota, Fate Therapeutics Inc | Bone Marrow Neoplasms; Multiple Myeloma | Details |
AFM-28 | AFM-28 | Phase 1 Clinical | Affimed | Leukemia, Promyelocytic, Acute; Neoplasms; Leukemia, Myeloid, Acute | Details |
SM-3321 | SM-3321; SM3321 | Phase 1 Clinical | Beijing StarMab BioMed Technology Ltd | Solid tumours; Neoplasms; Leukemia, Myeloid, Acute | Details |
FT-596 | FT-596 | Phase 1 Clinical | Fate Therapeutics Inc | Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
FT-516 | FT-516 | Phase 1 Clinical | University Of Minnesota, Fate Therapeutics Inc | Lymphoma, B-Cell; Ovarian Neoplasms; Solid tumours; Abdominal Neoplasms; Coronavirus Disease 2019 (COVID-19); Leukemia, Myeloid, Acute; Fallopian Tube Neoplasms | Details |
This web search service is supported by Google Inc.